No Data
Neumora Therapeutics' Head of R&D Sells Over $490k in Company Stock
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23
Needham analyst Ami Fadia maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 43.8% and a
Buy Rating on Neumora Therapeutics: Navigating Navacaprant's Potential in Neuropsychiatric Care
Neumora Therapeutics Price Target Maintained With a $29.00/Share by RBC Capital
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
RBC Capital analyst Brian Abrahams maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 48.2
RBC Capital Reaffirms Their Buy Rating on Neumora Therapeutics, Inc. (NMRA)